Antidiabetic DPP4 inhibitor Attenuates Intervertebral Disc Degeneration via Macrophage‐Nucleus Pulposus Cell Crosstalk
DPP4 was a causal driver of IVDD, and its inhibition by sitagliptin mitigated degeneration by disrupting the pathogenic positive feedback loop between macrophages and NP cells. These findings reposition sitagliptin, a clinically approved antidiabetic drug, as a promising therapeutic candidate for IVDD, highlighting the translational potential of targeting DPP4 and its downstream inflammatory cascades.
Authors
- Chen-Cheng Zhou
- Zihan Dai (ORCID: https://orcid.org/0000-0003-0103-2867)
- Yu‐rui Wu
- Yi‐Feng Shi
- Chenglong Xie (ORCID: https://orcid.org/0000-0003-3592-9058)
- Yi‐tian Yu
- Xiangcheng Zhang
- Wen‐Tian Cao
- Su‐Yu Ying
- Hai‐Wei Ma
- Gang Zheng
- Zhuo‐Fan Zeng
Institutions
- Wenzhou Medical University (CN)
- Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN)
- Lishui Central Hospital (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1111/bph.70283
- Primary Topic
- Spine and Intervertebral Disc Pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00